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Abstract  
Aims: Limited data exist on outcomes in very elderly ICD recipients. We describe outcomes 
in new ICD and Cardiac Resynchronisation Therapy with Defibrillator (CRT-D) implants in 
octogenarians  at  our  institution.                                                
Methods:  Patients  aged  80  years  and  above  who  underwent  de  novo  ICD  or  CRT-D 
implantation from January 2006 to July 2012 were identified. Clinical data were collected 
from the procedural record, medical and ICD notes. Baseline characteristics were compared 
using independent sample t test for continuous variables and Fisher's exact test for categorical 
variables.  Kaplan-Meier  curves  were  constructed.                            
Results: Ten per cent of all new ICD/CRT-D implants were aged 80 years and over. Median 
age was 83.0 years. Median follow-up was 29 months. Death occurred in 17 (34%). Median 
time  to  death  was  23  months.  Three  deaths  (6%)  occurred  within  12  months  of  ICD 
implantation.  Appropriate  therapy  (ATP  or  shock)  occurred  in  19  (38%).  Inappropriate 
therapy  occurred  in  6  (12%).                                         
Rates  of  appropriate  shocks  and  inappropriate  therapy  (shocks  and  ATP)  and  significant 
valvular incompetence were higher amongst deceased patients (P=0.03 OR 5.9 95% CI 1.3-
27) and (P=0.02 OR 12 95% CI 1.3-112). Univariate analysis identified diuretic use (P=0.008 
95% C.I. 0.05 to 0.63) and appropriate shock (P= 0.025 95% C.I. 1.25 to 26.3) as predictors 
of  mortality.                                   
Conclusion: Octogenarians make up a small but increasing number of ICD recipients. This 
study highlights  high  survival  rates  at  one  year  with  acceptable  rates  of  appropriate  and 
inappropriate device therapy. Ongoing debate regarding the appropriateness of ICD in very 
elderly  patients  is  warranted.                                              
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Introduction
Elderly patients were largely excluded from the pivotal studies in implantable cardioverter-
deﬁbrillators (ICDs) and therefore evidence of effectiveness in elderly patients is based on 
single centre studies and registry data. In the United Kingdom, there is an aging population. 
The Office of National Statistics estimates that in 2035, 5% of the population will be aged 85 
years and above, an increase of 250% compared to 2010. (UK Office of National statistics 
2014)  
Decisions  to  implant  ICDs  in  the  very  elderly  are  more  complex  due  to  associated  co-
morbidity and reduced life expectancy. Current guidelines recommend that ICD implantation 
should be considered in eligible patients if estimated survival is at least one year. [1] There is 
a  paucity  of  ICD  outcome  data  in  the  very  elderly  and  all  the  data  available  on  the 
octogenarians  and  nonagenarians  is  from  North-American  populations.  [2-5]  There  is 
therefore need for UK outcome data in this unique population of patients. We describe the 
outcomes in all new ICD and Cardiac Resynchronisation Therapy with Defibrillator (CRT-D) 
implants  in  octogenarians  at  our  institution.                                  
Materials  and  Methods                                    
All patients aged 80 years and above who underwent de novo ICD or CRT-D implantation 
from January 2006 to July 2012 at the Bristol Royal Infirmary (subsequently called Bristol 
Heart Institute) were identified from the hospital's ICD and CRT-D database. Clinical data for 
demographics, comorbidities and device therapy were collected from the procedural record, 
medical  notes and ICD notes.  The study was found to conform to the service evaluation 
standards  set  out  by  the  hospitals  Research  and  Development  department.           
Implant  and  follow  up                                      
All  devices  were  implanted  under  the  supervision  of  one  of  five  supervising  consultants 
working  in  the  cardiac  electrophysiology  department  during  the  study  period.  Implant 
technique  varied  between  physicians  according  to  preference  and  training.  Defibrillation 
testing was performed at the discretion of the implanting physician. Programming of monitor 
zone, anti-tachycardia pacing and defibrillation zones was at the discretion of the implanting 
physician.  Follow up was provided at  regular intervals of 3-6 months.                    
Endpoints
Clinical  outcome of  all-cause  mortality,  date  of  first  appropriate  shock  and  date  of  first 
inappropriate shock were collected from ICD interrogation records. Local referring centres 
were  contacted  to  ascertain  outcomes  in  cases  where  patients  had  been  followed  up 
elsewhere.  Information about device deactivation was collected.  The study data collection 
date  was  the  22nd  May  2013.                                                    
Definitions
Implant indication was defined as secondary prevention if the patient has survived a cardiac 
arrest  or experienced ventricular  tachyarrhythmia needing intervention or lasting for more 
than  30  seconds.  Primary  prevention  was  defined  as  the  absence  of  cardiac  arrest  or 
ventricular  tachyarrhythmia  requiring  intervention.  An  appropriate  shock  was  defined  as 
delivery of a defibrillation or cardioversion shock in the presence of VT/VF. An inappropriate 
shock was defined as the delivery of therapy in the absence of a ventricular tachyarrhythmia 
but  in  response  to  supraventricular  tachycardia,  oversensing  or  lead  malfunction.
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Statistical  analysis                                         
Categorical  variables  are  expressed  as  absolute  numbers  and  percentages.  Continuous 
variables were presented as mean standard deviation. Baseline characteristics of primary and 
secondary-prevention patients were compared using independent sample t-test for continuous 
variables and Fisher's exact test and Chi-squared test for categorical variables. Kaplan-Meier 
curves were constructed to determine cumulative incidence of mortality. Univariate analysis 
and multivariate analyses were performed to identify predictors of mortality. A P-value of 
less  than  0.05  was  considered  statistically  significant  for  all  tests.  Statistical  tests  were 
performed using Prizm for Mac OsX version 5.0c (Graphpad software, Inc.) and IBM SPSS 
statistics  version  21  (IBM  corp.)                                          
Results
Seventy-four de novo ICD or CRT-D recipients were aged 80 years and over in the study 
period  (10%  of  total  de  novo  implants).  The  proportion  of  octogenarians  receiving  an 
ICD/CRT-d increased over the study period. (Figure 1) 
Figure 1: Graph illustrating in change in proportion of octogenarians receiving de novo ICD / CRT-D over the 
study  period.  Percentages  indicate  percentage  octogenarian  /  total  number  receiving  ICD  /  CRT-D  x  100
Fifty patients met the inclusion criteria. (Table 1) 
Twenty-one patients (42%) received ICDs for primary prevention (PP) indications. (Table 2) 
PP patients had higher rate of CRT-D implant (P=0.02 95% CI 1.4-26).                       
Secondary prevention (SP) patients had higher rates of β blocker (P=0.01 95% CI 1.5-22), 
amiodarone (P=0.01 95% CI 1.5-27) and aspirin (P=0.01 95% CI 1.5-45) use. Kaplan-Meier 
survival curves were constructed for overall mortality (Figure 2) and mortality according to 
PP or SP indication (Figure 3). 
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Table 1: Study participant demographics in primary and secondary prevention categories.
Median age at implant was 83.0 (range 80-89.9) years. Median follow-up was 29 months 
(range 11-68 months). Death occurred in 17 (34%). Median time to death was 23 months 
(range 1-81 months). Three deaths (6%) occurred within 12 months of ICD implantation. 
Cause of death was pneumonia in 5, heart failure in 2, stroke in 1, malignancy in 1, sudden 
death  in  1  and  unknown  5.                                              
Figure 2: Kaplan-Meier survival curve of octogenarians with de novo ICD and CRT-D implants
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Figure 3: Kaplan-Meier survival curve of octogenarians according to implant indication. P=0.15
The survival curves according to indication were not statistically different (P=0.15). There 
was no significant difference in rates of appropriate or inappropriate shocks between the 2 
groups. (Table 3) There was trend towards increased appropriate therapy (ATP and shocks) 
in the SP group (P=0.14). 
Appropriate therapy (ATP or shock) occurred in 19 (38%) and inappropriate therapy occurred 
in 6 (12%). Kaplan-Meier curves for time to appropriate shock were constructed (Figure 4). 
Death occurred with no appropriate therapy in 10 (20%) patients.
Figure 4: Kaplan-Meier curve of time to appropriate therapy (ATP and shocks) for all patients. 
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Table 2: Study participant medication and co-morbidity in primary and secondary prevention 
categories.
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Table 3: Rates of ICD therapy, complication and deactivation amongst study participants in 
primary and secondary prevention categories. 
Rates of appropriate shocks and inappropriate therapy (shocks and ATP) were significantly 
higher amongst deceased patients (P=0.03 OR 5.9 95% CI 1.3-27) and (P=0.02 OR 12 95% 
CI 1.3-112).  Significant  valvular  incompetence was more common in the deceased group 
(P=0.05  OR  8.9  CI  0.91-87).                                    
Univariate analysis identified diuretic use (P=0.008 95% C.I. 0.05 to 0.63) and appropriate 
shock  (P=  0.025  95% C.I.  1.25  to  26.3)  as  predictors  of  mortality.  In  a  cox  regression 
multivariate analysis using the backward conditional method, only diuretic use was found to 
be a predictor of mortality (P=0.007 HR 4.0 95% C.I. 1.45 to 11.06).                                
Discussion
Decisions  to  implant  ICDs  in  elderly  patients  can  be  challenging  and  controversial. 
Proponents argue that patients benefit due to an increased incidence of sudden cardiac death 
(SCD) in this age group and age alone should not be a barrier to treatment. [6] Conversely,  
critics argue that the diminished life expectancy of elderly patients limit the potential benefit 
of  ICDs,  the  high  costs  of  implantation  and  follow up of  patients  are  not  offset  by  the 
potential gains and lastly SCD may seem an attractive proposition for some elderly patients 
with other significant co-morbidities.  Nevertheless, current international guidelines do not 
have an age cut off for ICD implantation. Guidelines state that potential candidates need to 
meet recommended criteria for implantation and have an estimated life expectancy of at least 
one  year.  [1]                                            
The elderly demonstrate an increased incidence of SCD. The annual incidence of SCD in an 
80-year-old male is  approximately seven times greater  than in a  40-year-old male.  [2] In 
women, this trend is more marked; the incidence of SCD in women aged over 70 years is 
more than 40 times greater than in women aged less than 45 years. [7,8] This phenomenon is 
attributable  to  the  increased  incidence  of  coronary  heart  disease  and heart  failure  in  the 
elderly population. However, despite this, the proportion of SCD to non-SCD diminishes in 
the elderly, a phenomenon referred to as the SCD paradox.  This is due to an even greater 
overall number of deaths in this age group. Moreover, the proportion of deaths attributable to 
pulseless  electrical  activity  (PEA),  a  condition  not  treatable  by  ICDs,  increases  with 
advancing  age.  [10]                                                  
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Evidence of effectiveness of ICDs in the elderly from clinical trials                                
Elderly patients are under-represented in ICD trials and analyses of their results have revealed 
mixed results.  The MADIT II  trial,  a primary prevention ICD trial,  included the greatest 
number  of  elderly  patients,  with  approximately  20% aged over  75  years.  In  a  sub-study 
analysis  of  this  study  evaluating  204  elderly  patients  (aged  more  than  75  years)  with 
ischaemic  cardiomyopathy,  an  equivalent  reduction  in  mortality  in  elderly  and  younger 
patients was found (hazard ratio hazard ratio, 0.56; 95% confidence interval,  0.29-1.08 vs 
0.56; 95% confidence interval 0.29-1.08). [11] However, it is important to note that follow up 
in over 75-year-old group was relatively short at 17.2 months. Thus the effect of subsequent 
non-SCD deaths affecting that population will not be accounted for and as a consequence, the 
overall benefit  derived from the ICD may be over-estimated.  In a meta-analysis involving 
three primary prevention trials, DEFINITE, MADTI II and SCD-Heft, a significant reduction 
in mortality was seen in elderly patients randomised to ICD therapy (HR 0.75, 95% CI 0.61-
0.91, P = 0.004). However, elderly patients were defined as over 60-65 years and most of the 
effect was driven by the MADIT II cohort, though the results are consistent with a previous 
meta-analysis of primary prevention ICD trials. [12] A meta-analysis of secondary prevention 
trials also failed to demonstrate the benefit of an ICD in the over 75 year old population. [13] 
Mortality
Knowledge of outcomes in very elderly ICD recipients can help inform clinicians in future 
implanting decisions. Overall annual mortality in this study was 14%. This is higher than the 
clinical trials described above where reported annual mortality in those who received ICDs 
ranged from approximately 5.8% to 8.5% per annum. [14-17] However, our mortality data is 
in line with registry data from Canada in which octogenarian patients receiving ICDs for 
primary and secondary prevention indication had 10.2 and 15.5 deaths per 100 person-years 
respectively. [2] Conversely, the 2-year mortality in a US registry of over 4,500 patients in 
which 12% of patients were aged over 80 years demonstrated more favourable mortality rates 
(17.8%) compared to ours (28%). [4] In healthcare systems with restrictive policies on ICD 
implantation, a 5% annual mortality is reported in their ICD recipients. [18]                     
In this study, rates of appropriate shock, inappropriate therapy and at least moderate valvular 
incompetence  were  statistically  more  common  in  the  deceased  patients.  However,  only 
diuretic  use and appropriate  shock were found to be statistically  significant  predictors  of 
mortality in multivariate analysis (hazard ratio 4.0). Similarly, other studies identified NYHA 
class, diuretic use, and peripheral vascular disease to be predictors of mortality in elderly 
patients with primary and secondary prevention indications for ICDs.   Appropriate shock has 
been found to be a predictor of death in some clinical trials. [19] The use of CRT is associated 
with improved survival  compared to  ICD alone  in  appropriately  selected  patients.  In this 
study, we did not find that CRT conferred reduced mortality, and this may be a reflection of 
the  relatively  small  numbers  included  in  the  study.                             
Appropriate  and  inappropriate  therapy                                       
In this study, rate of appropriate and inappropriate therapy occurred in 38% and 12% over the 
2.5 year follow up period. These are consistent with those reported in large European and 
Canadian ICD registries that in addition also reported no significant differences between rates 
of  appropriate  and  inappropriate  therapy  between  age  groups.  [2,20]  Furthermore,  older 
patients have been found to have lower rates of inappropriate therapy compared to younger 
patients, presumably due to lower incidence of sinus tachycardia as a cause of inappropriate 
shock and similarly impaired AV nodal conduction reducing ventricular rates during atrial 
arrhythmia.  [2]                                           
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Increasing numbers of elderly patients referred                                             
The proportion of octogenarians receiving ICDs in this study increased year on year until 
2010, from 2.9 % in 2006 to 12.7% of total implants in 2010. This trend is also seen in a large 
European ICD registry.  In another large US ICD registry, 10% of ICD recipients were aged 
80 years  and above.  [4]  US ICD data  has  been criticised  in  the  past  for  having a  large 
proportion  of  ICD implanted  outside  evidenced-based  criteria.  [21]  However,  potentially 
inappropriate rates of ICD use appear significantly lower in older than in younger Americans 
suggesting that even in very liberal ICD prescribing environment, physicians appear to be 
more conservative when referring older adults and deferring those with high co-morbidity. [3]
Selecting  ICD  recipients  appropriately                                  
When considering ICD patient selection there is a 'sweetspot' of effectiveness, where risk of 
SCD is elevated enough for the risks of ICD implantation to be outweighed by the benefits 
and for patient survival to be sufficiently long to maximise cost effectiveness. The MADIT II 
investigators identified a number of predictors of increased mortality (age more than 70 years, 
NYHA class more than II, impaired renal function, broad QRS and atrial fibrillation) and 
found  a  U  shaped  relationship  between  these  predictors  and  ICD  benefit.  Those  at  the 
extremes (very low and high risk of death) appeared to derive the least benefit from the ICD, 
whereas an intermediate score predicted the greatest benefit.  In our study, 12 patients had 
non-resynchronised ICDs for primary prevention and 11/12 (92%) had intermediate MADIT 
II  risk  scores  suggesting  they  had  been  well  selected  on  the  basis  of  relatively  few co-
morbidities. Age is an important variable in this equation, and is an independent predictor of 
death in ICD recipients. [20] So every decision to implant must be individualised and based 
on  fully  informed  consent.                                                   
End  of  life  and  deactivation                                            
ICDs were deactivated in 4 (8%) of the study participants.  Often this  was prior to  death 
occurring in hospital. One patient had requested deactivation of the ICD within one year of 
implantation and continues to be followed up and has not suffered any syncope or cardiac 
arrest. Data from analysis of the ICD patients who died the MADIT II trial identified 3 groups 
of patients: Group 1 consisting of individuals who underwent ICD, deactivation, 15 (15%); 
Group 2 patients without ICD deactivation who were in hospice or with "do not resuscitate" 
(DNR) orders, 36 (37%); and Group 3 patients without ICD deactivation who were not in 
hospice care and did not have DNR orders, 47 (48%).  [23] End of life discussions prior to 
ICD implantation  occurred  on a  patient-by-patient  basis  rather  than  a  systematic  fashion. 
Good practice suggests that fully informed consent should involve discussions regarding end 
of life issues and deactivation of ICDs. [24]                                              
Limitations
This study suffers form a number of limitations. It is a retrospective analysis of a relatively 
small number of patients. No comparator group was used as the principle aim of the study 
was to describe the outcomes of a unique ICD population rather than compare with a group 
who were almost by definition going to have improved outcomes.  Approximately one third 
of patients were not analysed due to incomplete data that limits the power of the analysis. 
Complications of ICDs were not specifically analysed although there is evidence to suggest 
that complications associated with ICD implantation are no greater in an elderly population. 
[2,5,20]  
In  conclusion,  this  is  the  first  report  from  the  UK  on  outcomes  in  octogenarian  ICD 
recipients. As with other series, the number of octogenarians referred for and receiving ICDs 
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is increasing. Mortality rates and rates of appropriate and inappropriate therapy are similar to 
North American and European series. This study highlights high survival rates at one year 
with  acceptable  rates  of  appropriate  and  inappropriate  device  therapy  during  follow  up. 
Importantly  however,  the cost effectiveness  of ICD implantation in octogenarians has not 
been examined. Ongoing debate regarding the appropriateness of ICD in very elderly patients 
is  warranted.                                       
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